<DOC>
	<DOCNO>NCT01334801</DOCNO>
	<brief_summary>This study do determine whether new blood test ( ) determine severity heart condition . Aortic stenosis , hypertrophic cardiomyopathy , mitral regurgitation , aortic regurgitation , artificial heart valve regurgitation stenosis , tricuspid valve regurgitation associate pacemaker lead cardiac disorder study . The blood test involve analysis von Willebrand Factor antigen activity , von Willebrand Factor multimers , brain natriuretic peptide ( BNP ) level . The result blood test compare information clinically-indicated echocardiogram one blood test compare another .</brief_summary>
	<brief_title>Biomarkers Aortic Stenosis - B.A.S.S .</brief_title>
	<detailed_description>Patients aortic stenosis , hypertrophic cardiomyopathy , mitral regurgitation , aortic regurgitation , artificial heart valve regurgitation stenosis , tricuspid valve regurgitation associate pacemaker lead refer clinically-indicated echocardiographic exam Mayo Clinic , Jacksonville , Florida screen participation study . The plan 292 people take part study . This minimal risk study consist record patient data , activity bleeding questionnaire , collection analysis blood sample . Each blood sample analyze von Willebrand Factor antigen activity , von Willebrand Factor multimers , BNP . Blood sample send Mayo Special Coagulation Lab analysis . Objective : This study seek assess degree association von Willebrand Factor activity index BNP severity cardiac lesion , note relationship acquire bleed hematologic abnormality . Plasma store attempt develop new vitro test von Willebrand factor ( VWF ) activity .</detailed_description>
	<mesh_term>Constriction , Pathologic</mesh_term>
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Hypertrophy</mesh_term>
	<mesh_term>Aortic Valve Stenosis</mesh_term>
	<mesh_term>Cardiomyopathy , Hypertrophic</mesh_term>
	<mesh_term>Aortic Valve Insufficiency</mesh_term>
	<mesh_term>Mitral Valve Insufficiency</mesh_term>
	<mesh_term>Tricuspid Valve Insufficiency</mesh_term>
	<mesh_term>Natriuretic Peptide , Brain</mesh_term>
	<criteria>patient mild , moderate , severe aortic stenosis aortic mitral prosthesis . Patients aortic mitral regurgitation . patient hypertrophic cardiomyopathy . Patients dysfunctional heart valve replacement repair . Patients severe tricuspid regurgitation associate pacemaker defibrillator lead . Ten normal control patient require echocardiography refer clinically indicated echocardiogram ; echo must good quality specifically patient height , weight , leave ventricular outflow tract diameter , subaortic velocity profile Doppler , aortic transvalvular continuous wave Doppler velocity profile . For mitral regurgitation aortic regurgitation data must adequate allow calculation regurgitant volume . For hypertrophic cardiomyopathy , record leave ventricular outflow tract peak velocity must record 21 year old patient aortic stenosis , define peak aortic velocity great 2.5 m/sec evidence aortic valve thickening , aortic mitral valve prosthesis able provide write informed consent Missing inadequate echocardiographic data inability give inform consent inability provide research blood sample hemoglobin le 8 severe valvular regurgitation stenosis mitral valve</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>aortic stenosis</keyword>
	<keyword>von Willebrand factor</keyword>
	<keyword>mitral valve replacement</keyword>
	<keyword>aortic valve replacement</keyword>
	<keyword>prosthetic valve dysfunction</keyword>
	<keyword>brain natriuretic peptide</keyword>
	<keyword>mitral valve regurgitation</keyword>
	<keyword>aortic valve regurgitation</keyword>
	<keyword>hypertrophic cardiomyopathy</keyword>
	<keyword>tricuspid insufficiency</keyword>
</DOC>